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Abstract
Background: Colon cancer (CRC) development often includes chromosomal instability (CIN) leading to amplifications and
deletions of large DNA segments. Epidemiological, clinical, and cytogenetic studies showed that there are considerable
differences between CRC tumors from African Americans (AAs) and Caucasian patients. In this study, we determined
genomic copy number aberrations in sporadic CRC tumors from AAs, in order to investigate possible explanations for the
observed disparities.
Methodology/Principal Findings: We applied genome-wide array comparative genome hybridization (aCGH) using a 105k
chip to identify copy number aberrations in samples from 15 AAs. In addition, we did a population comparative analysis
with aCGH data in Caucasians as well as with a widely publicized list of colon cancer genes (CAN genes). There was an
average of 20 aberrations per patient with more amplifications than deletions. Analysis of DNA copy number of frequently
altered chromosomes revealed that deletions occurred primarily in chromosomes 4, 8 and 18. Chromosomal duplications
occurred in more than 50% of cases on chromosomes 7, 8, 13, 20 and X. The CIN profile showed some differences when
compared to Caucasian alterations.
Conclusions/Significance: Chromosome X amplification in male patients and chromosomes 4, 8 and 18 deletions were
prominent aberrations in AAs. Some CAN genes were altered at high frequencies in AAs with EXOC4, EPHB6, GNAS, MLL3 and
TBX22 as the most frequently deleted genes and HAPLN1, ADAM29, SMAD2 and SMAD4 as the most frequently amplified
genes. The observed CIN may play a distinctive role in CRC in AAs.
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Introduction
Colorectal cancer is the third most common cancer in the
United States [1]. It has a higher incidence and causes more
deaths in African Americans than in other racial groups. Most
colorectal cancers arise from adenomas, in a process described
as the adenoma-carcinoma sequence [2]. Like other cancers,
initiation and progression of CRC are associated with an
accumulation of alterations in the function of key regulatory genes
and genetic instability.
Three major forms of genetic instability in CRC have been
described [2,3,4]. In about 13% of CRC cases, mismatch repair
deficiency leads to microsatellite instability (MIN)[5]. Approxi-
mately 40% of CRC tumors are characterized by epigenetic
changes especially DNA methylation, a phenomenon termed CpG
Islands Methylator Phenotype (CIMP) [6,7]. In the remaining
47% of CRCs, chromosomal instability leads to gains and losses of
large segments of chromosomes [8].
The CIN category includes cancers with aneuploid or
polypoid karyotypes, and cancers that have multiple gains or
deletions of chromosomal arms, or multiple translocations. CIN
results from specific mutations and/or genes being silenced and
could result from structural defects involving centromeres or
centrosome, microtubule dysfunction, telomeres erosion, chro-
mosome breakage and failure of cell cycle checkpoints [9]. The
acquisition of recurrent chromosomal gains and losses during
the progression from high-grade adenomas to invasive carcino-
mas is found in CRC tumors [10]. One of the earliest acquired
genetic abnormalities during CRC progression involves chro-
mosome 7 amplification, which is also observed in some colon
adenomas [11]. At later stages, other specific chromosomal
aberrations become common, such as gains on 8q, 20q [12], 7,
13 [13,14] and deletions on 8p, 17p, 18q [13,15] 15q and 20q
[16].
CIN and MIN phenotypes were initially considered mutually
exclusive since MIN tumors generally have stable and diploid
karyotypes [17,18]. However, recent studies have found that MIN
and CIN can occur in the same tumor [19,20]. Trautmann et al.
found that at least 50% of MSI-H tumors have some degree of
chromosomal alterations [21]. Although evidence for some degree
of CIN could be found in the majority of MSI-H tumors, the
specific alterations identified differed between MSI-H and MSS
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and losses of 15q and 18q while MSS tumors have a high degree
and variable chromosomal range of aberration [16,21].
Lassmann et al. studied 287 target sequences in 22 Caucasian
colorectal tumors and found frequent aberrations in specific
regions of chromosomes 7, 8, 13, 17, 20 and suggested some
candidate genes with frequent deletion or amplification in these
regions [22]. Studies that identify genes with altered copy number
associated with tumorigenesis may lead to the detection of specific
targets for cancer therapy and increase our understanding of
tumorigenesis. We hypothesize that identification of chromosomal
aberrations in CRCs from AA patients may help explain aspects of
colon cancer pathogenesis specific to this population. Therefore,
we investigated the CIN in AA CRC patients by applying aCGH
to tumor samples. We compared our results with the recently
published findings in Caucasians [22] and with a list of colon
cancer genes proposed by Sjo ¨blom et al [23] after their thorough
genetic analysis of 11 colon tumors.
Materials and Methods
Ethics Statement
This study was approved by Howard University Institutional
Review Board, and written informed consent was obtained.
Patients
Fresh frozen colonic biopsies (n=15) were obtained from
African-American patients undergoing colonoscopy at Howard
University Hospital. This study was approved by the Howard
University Institutional Review Board. The purpose of this
study was explained to the patients before colonoscopy and the
participating patients gave informed consent. Clinical data
collected on each patient included race, gender, associated past
medical history, medication use, and family history of colonic
cancer. Patients were deemed eligible if colonoscopy resulted in a
diagnosis of adenocarcinoma, confirmed by histopathology. From
the review of medical records, clinical information was collected
and recorded based on the American Joint Committee on Cancer
staging system. Patients in this study self-identified as AAs.
Samples Selection and DNA Extraction for aCGH Analysis
Fresh tumor blocks were cut into 5 mm sections on Superfrost
slides (Fisher Scientific, Pittsburgh, PA). The tumor and normal
areas were distinguished by a pathologist (E.L) using the H&E
matched slide and microdissected to pinpoint the tumor as well as
normal areas. Tumor and normal corresponding areas from fresh
frozen samples were used for DNA extraction using Puregene kit
(San Francisco, CA) according to the manufacturer’s instructions.
The goal of the microdissection was to avoid the cross
contamination of normal and tumor tissues which would impact
the outcome of the aCGH experiment.
aCGH Experiments and Statistical Data Analysis
In this experiment, we studied the profile of chromosome
aberrations in 15 colon adenocarcinomas. Our reference controls
were either matched normal or sex-matched normal DNA with no
history of any disease to determine the impact of chromosomal
aberrations by aCGH in AA colon adenocarcinomas. The colon
tissues were evaluated by a GI pathologist for proper histological
features that were used for this study including the size, type,
location and pathological criteria of the carcinomas. An oligo
microarray-based CGH using a chip containing 105,000 human
probes (Agilent, Santa Clara, CA) was used. The carcinomas were
defined histologically and then after confirmation by the
pathologist, we used the corresponding fresh–frozen tissue.
For each aCGH experiment, 1.5 mg of reference DNA and
1.5 mg of one tumor DNA were used. Briefly, the test and
reference DNAs were digested with Alu I and Rsa I (Promega,
Madison, WI), and purified with the QIAprep Spin Miniprep kit
(QIAGEN, Germantown, MD). Test DNA (1.5 mg) and reference
DNA (1.5 mg; Promega) were labeled by random priming with
Cy5-dUTP and Cy3-dUTP, respectively, using the Agilent
Genomic DNA Labeling Kit Plus. Following the labeling reaction,
the individually labeled test and reference samples were concen-
trated using Microcon YM-30 filters (Millipore, Billerica, MA) and
then combined. Following probe denaturation and pre-annealing
with Cot-1 DNA, hybridization was performed at 65uC with
rotation for 40 hr at 20 rpm. Four steps were done with Agilent
Oligo CGH washing solutions: wash buffer 1 at room temperature
for 5 min, wash buffer 2 at 37uC for 1 min, an acetonitrile rinse at
room temperature for 1 min and a 30 sec wash at room
temperature in Agilent’s Stabilization and Drying Solution. Copy
number variations (CNVs) were identified by Agilent Feature
Extraction software 9 and analyzed with Agilent CGH analytics
3.4 software, using the statistical algorithms z score and ADM-2
using sensitivity thresholds of 2.5 and 9, respectively and a moving
average window of 0.2 Mb. Locations of CNVs were reported with
respect to the human genome sequence assembly Build 35, Hg17
(www.ncbi.nlm.nih.gov).
Analysis of Gene Content of CNVs
Names of genes suggested in [22,23] were standardized using
the HUGO Gene Nomenclature Committee web site (www.
genename.org). Positions of these genes were determined using the
data files underlying NCBI’s MapViewer browser (www.ncbi.nlm.
nih.gov/mapview). Using software newly developed for this study,
we identified each overlap between candidate genes and CNVs
such that the gain or loss ratio was more extreme than a user-
specified threshold for the ratio. For the results shown below, we
used the thresholds of $1.2 and #0.8 for gains and losses,
respectively. The software takes as inputs:
1) A file of genes with the chromosome, start position, and end
position of each gene;
2) A list of CNVs specifying the start, end, and ratio of each
gene;
3) Thresholds for gains and losses.
The software reports every gene such that there is an
intersecting gain/loss whose ratio is above/below the user-
specified ratios. For example the gene APC is located on human
chromosome 5 in the interval [112101484, 112209836]. Two
patients have losses with ratios ,0.8 intersecting the interval
[112101484, 112209836] and seven patients have gains with ratios
.1.2 intersecting the same interval. The same thresholds were
used in the study [22], with which we compared our results.
Summary statistics on the amplifications and deletions were
tabulated within the new software and using Excel.
Results
Characteristics of the Analyzed Samples
We studied 15 colon adenocarcinomas from AA patients. The
mean age of this group of patients was 63.5 years with eight
females and seven males. The tumors were mainly moderately
differentiated (93%), and in stage II or III (87%). Two thirds of the
samples were right sided (67%; Table 1). A comparison of our
aCGH of Colon Cancer
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statistically significant differences between the two groups
(Table 1).
Summary of Genomic Alterations
All 15 cases displayed some chromosomal instability. These
chromosomal aberrations were not equally distributed over all the
chromosomes. Only chromosome 21 did not show any amplifi-
cations and only chromosome 8 did not show any deletions. A
total of 182 amplification events and 101 deletion events were
found in the 15 samples all together, with mean counts of 12.1
amplifications and 6.7 deletions per patient. average of 20
aberrations were found in each patient on this study. Amplifica-
tions were prominent in chromosomes 2 (40%), 6 (47%), 7 (80%),
8 (60%), 12 (40%), 13 (60%), 16 (47%), 20 (67%) and X (60%).
Chromosomal deletions were more frequent on chromosomes 2
(47%), 4 (53%), 5 (60%), 7 (40%), 8 (67%), 17 (40%), 18 (60%), 19
(40%), and 22 (40%; Table 2).
The aberrations were unequally distributed among the 15
patients with four patients having less than 10 aberrations (patients
3, 11, 12 and 13). The number of aberrations does not seem to be
stage-specific since these four patients are at stages 1, 3c, 3c, and
3a respectively. Other patients at these stages displayed many
more aberrations (patients 2, 4, 5, 8, 9, 10, 11 and 13). The
number of CNVs does not seem to depend on the age of the
patients since patients 1 and 2, the youngest in our group (51 and
53 years old), have 55 and 42 aberrations respectively, while
patients 3, 11, 12 and 13 with the fewest number of aberrations are
65, 83, 73 and 61 years old, respectively. Also, there was no
correlation between gender and the frequency of CNVs.
Comparison of the aCGH Data with the CRC CAN Genes
An analysis by Sjo ¨blom et al. [23] of 11 breast and 11 colon
tumors led to the establishment of a list of potentially altered genes
in these kinds of tumors. More than 90% of the tumors were stage
IV in Sjo ¨blom et al compared to 6.6% in this study. We checked
our aCGH data for gains/losses of the 68 genes that were found to
be generally altered in colon cancer tumors. Most of these genes
show a non-zero frequency of alteration in our samples. Among
the CRC genes established by Sjo ¨bolm et al [23], the most
commonly deleted in our samples were EPHB6, EXOC4 (SEC8L1),
GNAS, MLL3, and TBX22. The most commonly amplified genes
were HAPLN1(CRTL1), ADAM29, SMAD2, and SMAD4 (Table 3).
Comparative Analysis of aCGH Data between AAs and
Caucasians
We compared our aCGH data of AA patients with the list of
most deleted or amplified genes obtained with Caucasian tumor
tissues by Lassmann et al. [22]. The colorectal cancers in our study
were more than 90% moderately differentiated which is similar to
the Lassmann et al study. However, the proportions of stage II and
III tumors were 68% and 32% in Lassmann et al and 33%, 53%
in this study. Our comparison revealed that 29 genes have a
similar pattern of alterations in both populations while 13 genes
displayed different profiles (Table 4). Of these 13 genes, the ATM
gene was mainly amplified in Caucasians. The DCC gene was
mainly amplified in Caucasians but deleted in AAs (p,0.05).
EGR2, FLII, LLGL1, MAP2K5, PCNT, RAF1, SP6, THRB, and
TOP3A genes were deleted in Caucasians but unaltered in AA
patients. Six genes were deleted in AAs but not in Caucasians with
statistically significant differences namely; ATM, INS, KAL1,
LRRC32, TOP3A and XIST (Table 4). The STS gene was deleted
Table 1. Clinical and demographic characteristics of the 15
patients enrolled in this study.
Case number Age Sex Stage Location Differentiation
1 53 Female 4 Right Colon Moderately
2 51 Female 2a Left Colon Moderately
3 65 Male 1 Right Colon Moderately
4 71 Male 2b Left Colon Moderately
5 69 Female 2a Left Colon Moderately
6 65 Female 2a Left Colon Moderately
7 57 Male 3b Right Colon Moderately
8 65 Male 3b Left Colon Well
9 68 Female 3c Right Colon Moderately
10 64 Male 3c Right Colon Moderately
11 83 Female 3c Right Colon Moderately
12 73 Female 3c Right Colon Moderately
13 61 Male 3a Right Colon Moderately
14 54 Female 2a Right Colon Moderately
15 53 Male 3c Right Colon Moderately
doi:10.1371/journal.pone.0008879.t001












1 3 (3) 20 8 (5) 33.3
2 8 (6) 40 8 (7) 46.6
3 5 (4) 26.6 10 (4) 26.6
4 6 (5) 33.3 9 (8) 53.3
5 8 (4) 26.6 12 (9) 60
6 8 (7) 46.6 10 (5) 33.3
7 12 (12) 80 11 (6) 40
8 10 (9) 60 14 (10) 66.6
9 3 (3) 20 0 0
10 6 (5) 33.3 7 (5) 33.3
11 3 (3) 20 5 (5) 33.3
12 11 (6) 40 4 (4) 26.6
13 9 (9) 60 4 (2) 13.3
14 3 (1) 6 3 (3) 20
15 5 (4) 26.6 6 (5) 33.3
16 7 (7) 46.6 2 (2) 13.3
17 6 (6) 26.6 6 (6) 40
18 5 (4) 26.6 12 (9) 60
19 4 (4) 26.6 6 (6) 40
20 10 (10) 66.6 3 (3) 20
21 0 0 5 (5) 33.3
22 1 (1) 6 6 (6) 40
X 10 (9) 60 3 (3) 20
Y 2 (2) 28.6 3 (3) 42.8
*Footnote: 3(3) means 3 amplification in 3 cases; 8 (5) means 8 deletions in 5
cases from total of 15 for the calculated frequency.
doi:10.1371/journal.pone.0008879.t002
aCGH of Colon Cancer
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amplified in AAs and unaltered in Caucasians (Table 4). The
method of comparison precluded identifying genes that are
frequently altered in AAs, but not included in the Lassmann et
al study.
Discussion
To decipher the possible genetic reasons underlying the high
incidence of colon cancer in AAs, we earlier conducted studies on
the MSI, methylation of CAN genes and mutations of known
genes such as BRAF and KRAS [24,25,26]. While these studies
revealed some of the genetic and epigenetic specifics in this
population, none have shown any striking differences between AAs
and the general population. We here conducted the first analysis of
the whole genome of colon tumors from AA patients with the goal
of having a more comprehensive view of the genomic regions
involved in colon carcinogenesis. We compared our findings with
those published on Caucasian samples [22] and with a widely-
publicized list of colon cancer genes [23].
An average of 20 aberrations were found in the analyzed tumors
strengthening the role of chromosomal instability in colon
carcinogenesis in this population with more amplification (12.13
per case) than deletions (6.73 per case) pointing towards a higher
role for oncogenes activation than tumor suppressor genes
deactivation in this process. The CRC alterations targeted certain
Table 3. Status of the 68 genes from Sjo ¨blom et al. list (23) in








ABCA1 9q31.1 4 (26) 0 (0)
ACSL5 10q25 1 (6) 3 (20)
ADAM29 4q34 0 (0) 8 (53)
ADAMTS15 11q25 2 (13) 2 (13)
ADAMTS18 16q23 7 (46) 3 (20)
ADAMTSL3 15q25.2 2 (13) 3 (20)
APC 5q22 2 (13) 7 (46)
C10orf137 10q26.1 1 (6) 2 (13)
C15orf2 15q11 0 (0) 5 (38)
CD109 6q13 5 (38) 3 (20)
CD248 11q13 5 (38) 3 (20)
CD46(MCP) 1q32 2 (13) 0 (0)
CHL1 3p26.1 3 (20) 0 (0)
CNTN4 3p26 2 (13) 1 (6)
CSMD3 8q23.3 9 (60) 0 (0)
EPHA3 3p11.2 2 (13) 2 (13)
EPHB6 7q34 12 (80) 0 (0)
ERCC6 10q11.2 4 (26) 2 (13)
ERGIC3(SBDCAG84) 20q12 10 (66) 1 (6)
EVL 14q32.2 1 (6) 3 (20)
EXOC4(SEC8L1) 7q31 12 (80) 0 (0)
EYA4 6q23 3 (20) 4 (26)
FBXW7 4q31.3 0 (0) 5 (38)
GALNS 16q24.3 4 (26) 3 (20)
GNAS 20q13.3 10 (66) 1 (6)
GUCY1A2 11q22 4 (26) 3 (20)
HAPLN1 5q14.3 1 (6) 7 (46)
HIST1H1B 6p22 8 (53) 1 (6)
KCNQ5 6q14 5 (38) 3 (20)
KIAA1409 14q32.1 0 (0) 2 (13)
KRAS 12p12.1 6 (40) 0 (0)
KRT73(K6IRS3) 12q13.3 5 (38) 1 (6)
LGR6 1q32.1 2 (13) 1 (6)
LMO7 13q22.2 10 (66) 2 (13)
LRP2 2q31 4 (26) 1 (6)
MAP2 2q34-35 4 (26) 1 (6)
ACTL9 19p13.2 4 (26) 6 (40)
MKRN3 15q11 0 (0) 4 (26)
MLL3 7q36.1 12 (80) 0 (0)
MMP2 16q12-13 8 (53) 4 (26)
NF1 17q11.2 8 (53) 2 (13)
OBSCN 1q42.1 2 (13) 1 (6)
P2RX7 12q24 6 (40) 2 (13)
P2RY14 3q25 5 (38) 0 (0)
PHIP 6q14 5 (38) 3 (20)
PKHD1 6p12.2 7 (46) 3 (20)
PKNOX1 21q22.3 0 (0) 5 (38)








PTPRD 9p23-24 4 (26) 0 (0)
PTPRU 1p35 3 (20) 6 (40)
RET 10q11.2 3 (20) 1 (6)
RUNX1T1 8q22 9 (60) 0 (0)
SCN3B 11q23.3 4 (26) 2 (13)
SFRS6 20q13.1 10 (66) 1 (6)
SLC29A1 6p21 9 (60) 4 (26)
SLC44A4(C6orf29) 6p21.3 8 (53) 1 (6)
SMAD2 18q21.1 0 (0) 9 (60)
SMAD3 15q22.3 2 (13) 3 (20)
SMAD4 18q21.1 0 (0) 9 (60)
SYNE1 6q25 3 (20) 4 (26)
TBX22 Xq21.1 11 (73) 3 (20)
TCF7L2 10q25.3 1 (6) 3 (20)
TGFBR2 3p22 2 (13) 0 (0)
TP53 17p13.1 4 (26) 7 (46)
TTLL3 3p25.3 2 (13) 0 (0)
UHRF2 9p24.1 4 (26) 0 (0)
UQCRC2 16p12 8 (53) 3 (20)
ZNF442 19p13.2 4 (26) 6 (40)
Grand Total 300 176
The most frequently deleted genes in our samples were EPHB6, EXOC4 (SEC8L1),
GNAS, MLL3 and TBX22. The most frequently amplified genes were HAPLN1,
ADAM29, SMAD2 and SMAD4. Gene names are according to the official HUGO
Gene Nomenclature Committee and the old names in parentheses are from
Sjo ¨blom et al.
doi:10.1371/journal.pone.0008879.t003
Table 3. Cont.
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were amplified in more than 50% of the cases in this study. It is
established that chromosomes 7, 8, 13 and 20 are involved in
CRC through amplification [22]. Our findings suggest the
additional importance of chromosome X, which was amplified
in 60% of cases. Many publications refer to chromosome X
containing tumor suppressor genes detected after deletions in
tumors [27]. Amplification of chromosome X p and q arms
Table 4. Distribution of TSG and oncogenes aberrations in African Americans and Caucasians reported by Lassmann et al (22).
Lassmann et al. African Americans
Gene Chromosome band Amplified (%) Deleted (%) Amplified (%) Deleted (%)
THRB 3p24.3 32 0 0
RAF1 3p25 14 0 0
RFC2 7q11.2 36 33 0
CYLN2 7q11.23 36 33 0
MET 7q31 23 33 0
LPL 8p22 23 0 33
E2F5 8q22-q21.3 36 28 0
LPL 8p22 23 0 33
EXT1 8q24.11-q24.13 32 28 0
MYC 8q24.12-q24.13 36 28 0
EGR2 10q21.3 23 0 6
DMBT1 10q25.3-q26.1 23 0 11
LRRC32 11q13.5 32 6 17
ATM 11q22.3 27 6 17
INS 11p tel 32 6 17
BRCA2 13q12-q13 36 22 0
RB1 13q14 41 22 0
MAP2K5 15q23 32 0 11
SP6 17ptel 23 6 6
TOP3A 17p11.2 03 3
LLGL1 17p12-17p11.2 36 0 33
FLII 17p12-17p11.2 23 0 33
HIC1 17p13.3 32 0 28
CTDP1 18q tel 45 0 22
LAMA3 18q11.2 14 0 17
BCL2 18q21.3 23 0 22
DCC 18q21.3 32 18 0 28
TPD52L2 20qtel 27 33 0
TOP1 20q12-q13.1 32 33 6
TNFRSF6B 20q13 32 33 0
NCOA3 20q13 32 33 6
AURKA 20q13 36 33 6
CSE1L 20q13 27 33 6
MYBL2 20q13.1 32 33 6
PTPN1 20q13.1-q13.2 23 33 6
CYP24A1 20q13.2 36 33 6
ZNF217 20q13.2 32 33 6
PRPF6 20q13.3 27 33 0
PCNT 21qtel 18 0 22
XIST Xq13.2 36 22 17
STS Xp22.3 23 17 17
KAL1 Xp22.3 36 17 17
The genes listed are the forty-two genes in the Lassmann et al. report, but in some cases the name has been changed to conform with the HUGO Gene Nomenclature
Committee recommendations. Markers for microsatellites in Lassmann et al. list were dropped in this comparison.
doi:10.1371/journal.pone.0008879.t004
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than the female ones (2 out of 8 (25%)). A study of Japanese CRC
patients found similarly that gains on chromosome X are more
prominent in male than female patients [28].
In our subgroup of 7 male patients, 3 (42.8%) displayed a
deletion of a common region spanning from Yq11.223 through the
centromere to the Yp11.31 band. There is debate over the possible
role of the Y chromosomal losses in diseases such as acute myeloge-
nous leukemia or whether such a process is just age related [29].
Patients 4, 7 and 10 with Y chromosomal deletions are 71, 57 and 64
years old respectively. A larger male CRC population is needed to sort
out the role this chromosome might play in colon cancer.
Chromosomes on which deletions are known to be frequent in
CRC are 8, 15, 17 and 18 [22]. In our group, chromosomes 4, 8
and 18 displayed deletions in more than 50% of cases while
chromosomes 15 and 17 were deleted at frequencies of 33.3% and
40% respectively. Thus, by the measure of chromosomes with
frequent deletions, CRC in AAs appears to be similar to CRC in
Caucasians.
We checked the list of 68 genes from Sjo ¨blom et al [23] that are
potentially involved in colon cancer to see the status of those genes
in our group of patients. All of these genes show some level of
alteration (amplification or deletion) in our patients. These results
strengthen their CAN gene status (Table 3). One of the most
deleted genes was EPHB6 that is known to slow breast cancer cell
lines invasiveness [30]. Another gene EXOC4 (SEC8L1), which
contains a polymorphism associated with type 2 diabetes [31] was
also frequently deleted in our samples, and is known to play a role
in synaptogenesis and brain development [32]. The protein
EXOC4 is part of the exocyst complex that has been implicated in
breast cancer invasiveness [33]. The MLL3 gene is not altered in
Korean CRC patients [34] and rarely altered in another study
[35], but it is one of the most frequent targets of deletion in our
group of patients. The GNAS gene whose expression increases
Galphas expression is a proapoptotic gene involved in many solid
organ cancers [36]. Its function is consistent with our finding that
it is also highly deleted in AA CRC patients. Mutations in the
frequently deleted gene TBX22 are linked to non-syndromic cleft
palate [37], but TBX2 has no known role in tumorigenesis.
Among the CAN genes from Sjo ¨blom et al. list [23], the
following are among the most frequently amplified in AA patients:
SMAD2, SMAD4, ADAM29, and HAPLN1. Proteins of the ADAM
family are a group of metalloproteinase of which ADAM17 is the
most studied. ADAM17 is required for the generation of the active
forms of Epidermal Growth Factor Receptor (EGFR) ligands, and
its function is essential for the development of epithelial tissues
[38]. Should ADAM29 also function to activate growth receptors,
then its amplification in tumors would make sense. The HAPLN1
(CRTL1) gene encodes an extracellular matrix protein, that plays
an important role in heart development [39]. The expression of
HAPLN1 may be altered during colorectal carcinogenesis [40].
Both SMAD2 and SMAD4 are known to be involved in cell
proliferation, apoptosis and differentiation through the TGF
pathway [41]. As such, their amplification might be instrumental
in growth promotion and carcinogenesis along with other genes.
We checked 42 CRC genes suggested by Lassmann et al. to be
frequent targets of CNVs [22]. We comment on a few of the genes
for which the Caucasian and AA samples showed different
patterns of aberrations. The ATM gene, whose encoded protein is
essential for DNA damage response and contributes to cellular
homeostasis [42], was frequently amplified in Caucasian patients
but not in the AA group. On the other hand, PRPF6 is only
amplified in AAs (Table 4). Mutations in genes from the same
family (PRPF3, 8, and 31) have been implicated in retinitis
pigmentosa [43]. However, no role in cancer of PRPF6 or other
related genes is known. Two genes showed opposite alterations in
the two patient groups; DCC was primarily amplified in
Caucasians but deleted in AAs, while the STS gene was deleted
in Caucasians and amplified in AAs. Indeed, DCC is generally
down-regulated or deleted in colon cancer patients owing to its
TSG properties which is more consistent with its deletion status
using aCGH in our patients [44]. The constitutive expression of
STS gene (steroid sulfatase gene) promotes the growth of human
breast cancer cells [45]. While the differences between Lassmann
et al, Sjo ¨blom et al [22,23] and our study might be in part due to
the level of chromosomal aberration, the data within our study
showed that neither the tumor stage nor the differentiation status
had an effect on chromosomal instability. Future studies are
needed where stage and differentiation matched tumors from
different populations are evaluated.
In conclusion, our aCGH analysis of 15 AA colorectal
carcinomas shows that all tumors contain some level of
chromosomal instability. Georgiades et al. have identified a group
of carcinomas with no CIN [4]. Such is not the case for our AA
patients. A larger number of patients is needed to investigate
whether such CRC tumors exist within AAs or all AA CRCs have
some levels of CIN. A more comprehensive analysis involving MSI
and methylation profiles of the analyzed tumors, in addition to
CIN analysis might also shed more light on the intricacies and
specificities of these different processes in tumorigenesis. The role
of Chromosome X amplification in colon carcinogenesis in AA
patients, particularly males, merits further investigation.
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